Abstract
To assess the safety and efficacy of a Food and Drug Administration-approved pathogen-reduced platelet (PLT) product in children, as ongoing questions regarding their use in this population remain. We report findings from a quality assurance review of PLT utilization, associated red blood cell transfusion trends, and short-term safety of conventional vs pathogen-reduced PLTs over a 21-month period while transitioning from conventional to pathogen-reduced PLTs at a large, tertiary care hospital. We assessed utilization in neonatal intensive care unit (NICU) patients, infants 0-1year not in the NICU, and children age 1-18years (PED). In the 48hours after an index conventional or pathogen-reduced platelet transfusion, respectively, NICU patients received 1.0±1.4 (n=91 transfusions) compared with 1.2±1.3 (n=145) additional platelet doses (P=.29); infants 0-1year not in the NICU received 2.8±3.0 (n=125) vs 2.6±2.6 (n=254) additional platelet doses (P=.57); and PEDs received 0.9±1.6 (n=644) vs 1.4±2.2 (n=673) additional doses (P< .001). Time to subsequent transfusion and red cell utilization were similar in every group (P> .05). The number and type of transfusion reactions did not significantly vary based on PLT type and no rashes were reported in NICU patients receiving phototherapy and pathogen-reduced PLTs. Conventional and pathogen-reduced PLTs had similar utilization patterns in our pediatric populations. A small, but statistically significant, increase in transfusions was noted following pathogen-reduced PLT transfusion in PED patients, but not in other groups. Red cell utilization and transfusion reactions were similar for both products in all age groups.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.